Tempus AI Makes Billion-Dollar Bet on the Future of Cancer Monitoring

Benzinga_recent_news07-22 02:52

Tempus AI shares erased early losses and recovered after an initial selloff tied to the company’s acquisition of Personalis. The acquisition, valued at $1.5 billion, is set to expand Tempus’ reach in ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2653200535?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/cdn-cgi/image/width=3840,format=auto,quality=85/files/images/story/2026/07/21/Stock-Update.jpg","is_english":true,"pubTime":"2026-07-22 02:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2653200535","market":"us","top_or_hot":-1,"title":"Tempus AI Makes Billion-Dollar Bet on the Future of Cancer Monitoring","media":"Benzinga_recent_news","content":"<div>\n<p>Tempus AI shares erased early losses and recovered after an initial selloff tied to the company’s acquisition of Personalis.\nThe acquisition, valued at $1.5 billion, is set to expand Tempus’ reach in ...</p>\n\n<a href=\"https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/07/60591588/tempus-ai-makes-billion-dollar-bet-on-the-future-of-cancer-monitoring\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tempus AI Makes Billion-Dollar Bet on the Future of Cancer Monitoring</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTempus AI Makes Billion-Dollar Bet on the Future of Cancer Monitoring\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-22 02:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/07/60591588/tempus-ai-makes-billion-dollar-bet-on-the-future-of-cancer-monitoring><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tempus AI shares erased early losses and recovered after an initial selloff tied to the company’s acquisition of Personalis.\nThe acquisition, valued at $1.5 billion, is set to expand Tempus’ reach in ...</p>\n\n<a href=\"https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/07/60591588/tempus-ai-makes-billion-dollar-bet-on-the-future-of-cancer-monitoring\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HEAL","symbol_name":"Global X HealthTech ETF","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/07/60591588/tempus-ai-makes-billion-dollar-bet-on-the-future-of-cancer-monitoring","article_id":"2653200535","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/cdn-cgi/image/width=3840,format=auto,quality=85/files/images/story/2026/07/21/Stock-Update.jpg"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/07/60591588/tempus-ai-makes-billion-dollar-bet-on-the-future-of-cancer-monitoring","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2653200535","pubTimestamp":1784659920,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Tempus AI acquires Personalis for $1.5B to target the $20B MRD cancer monitoring market. Get full deal details and analysis.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"HEAL":"Global X HealthTech ETF","BK4613":"AI应用软件","TEMT":"2倍做多TEM ETF-Tradr","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4611":"AI医疗","LU1861558580.USD":"日兴方舟颠覆性创新基金B","ARKG":"ARK Genomic Revolution ETF","TEM":"Tempus AI","PSNL":"Personalis","BK4121":"生命科学工具和服务"},"translate_title":"Tempus AI 押注癌症监测的未来","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HEAL":0.6,"ARKG":0.6,"TEM":1.97,"TEMT":0.6,"PSNL":1.88},"content_text":"Tempus AI shares erased early losses and recovered after an initial selloff tied to the company’s acquisition of Personalis.\nThe acquisition, valued at $1.5 billion, is set to expand Tempus’ reach in the MRD market. Tempus claims it presents a $20 billion opportunity.\nWilliam Blair has a favorable view of the strategic fit and expects Personalis’ growth and profitability trajectory to be meaningfully different inside of Tempus than it would have been as a standalone company.\nThe acquisition multiple is high at ~14 times 2027 consensus sales, though analyst Matt Larew wrote that the consensus likely understates Personalis’ 2027 revenue outlook given recent MolDX approvals and Tempus’ ability to further leverage its commercial infrastructure.\nThe other pressure point will be profitability given Personalis’ clear loss-making position (consensus adjusted EBITDA of -$90 million for 2027) and Tempus’s commitment to be EBITDA and FCF positive in 2027.\nManagement argued that the timing of the acquisition is coincident with Personalis reaching an inflection point, with several years of commercial and reimbursement investment likely to yield enhanced ASPs and margins moving forward.\nWilliam Blair rates Tempus AI shares Market Perform. For multiple expansion to materialize, analyst Larew expects investors will want to see additional positive proof points on recent M&A contributing to numbers and more clarity on the growth profile and durability of the data business.\nAnalyst Navann Ty wrote that Natera maintains a defensible, leadership position in the space, with a solid pipeline of ongoing clinical trials.\nBNP Paribas maintains Neutral on Natera as the company continues to progress towards catalysts but views the current valuation as fair.\nTEM Stock Price Activity: Tempus AI shares were up 1.96% at $49.36 at the time of publication on Tuesday, according to Benzinga Pro data.\nPhoto via Shutterstock\nTo add Benzinga News as your preferred source on Google, click here.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2653200535","isCrawlerRequest":true}